[Clinical Characteristics and Prognosis of Patients with IgD Multiple Myeloma].
The incidence of IgD MM is low, the symptoms of early renal damage, blood system damage and bone erosion in IgD MM patients are obvious, and the median survival time is short. ASCT and / or daratumumab may bring lasting relief for IgD MM patients, but large-scale clinical studies are still needed.
Authors
- Qiaolin Chen
- Xiaofang Wei (ORCID: https://orcid.org/0000-0003-1588-8797)
- Qike Zhang
- Yongqian Zhang (ORCID: https://orcid.org/0000-0001-6966-1366)
- Ji‐Sheng Zhao
- Yuan Fu
- You-Fan Feng
Institutions
- Longdong University (CN)
- Gansu Provincial Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.018
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article